Our top pick for
Building a portfolio
InterPrivate Acquisition Corp is a shell companies business based in the US. InterPrivate Acquisition shares (IPV) are listed on the NYSE and all prices are listed in US Dollars.
|52-week range||$9.15 - $20.85|
|50-day moving average||$15.89|
|200-day moving average||$12.99|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.04|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing InterPrivate Acquisition stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of InterPrivate Acquisition's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
InterPrivate Acquisition's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 446x. In other words, InterPrivate Acquisition shares trade at around 446x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Gross profit TTM||$0|
|Return on assets TTM||-1.3%|
|Return on equity TTM||-37.13%|
|Market capitalisation||$405 million|
TTM: trailing 12 months
There are currently 701,913 InterPrivate Acquisition shares held short by investors – that's known as InterPrivate Acquisition's "short interest". This figure is 212.6% up from 224,516 last month.
There are a few different ways that this level of interest in shorting InterPrivate Acquisition shares can be evaluated.
InterPrivate Acquisition's "short interest ratio" (SIR) is the quantity of InterPrivate Acquisition shares currently shorted divided by the average quantity of InterPrivate Acquisition shares traded daily (recently around 1.3 million). InterPrivate Acquisition's SIR currently stands at 0.53. In other words for every 100,000 InterPrivate Acquisition shares traded daily on the market, roughly 530 shares are currently held short.
However InterPrivate Acquisition's short interest can also be evaluated against the total number of InterPrivate Acquisition shares, or, against the total number of tradable InterPrivate Acquisition shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InterPrivate Acquisition's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 InterPrivate Acquisition shares in existence, roughly 20 shares are currently held short) or 0.0286% of the tradable shares (for every 100,000 tradable InterPrivate Acquisition shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InterPrivate Acquisition.
Find out more about how you can short InterPrivate Acquisition stock.
We're not expecting InterPrivate Acquisition to pay a dividend over the next 12 months.
As of March 12, 2021, InterPrivate Acquisition Corp. was acquired by AEVA, INC. , in a reverse merger transaction. Interprivate Acquisition Corp. does not have significant operations. It focuses on the merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded in 2019 and is based in New York, New York.
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.